小羅伯特甘迺迪 (Robert F. Kennedy Jr.) 被提名領導 HHS，Moderna 股價下跌

在當選總統唐納德·川普提名小羅伯特·F·甘迺迪領導衛生與公眾服務部後，Moderna Inc. 的股價下跌。

Shares of Moderna Inc (NASDAQ:MRNA) are trading lower after President-elect Donald Trump nominated Robert F. Kennedy Jr. to lead the Department of Health and Human Services. Here’s what you need to know.

在當選總統唐納德·川普提名小羅伯特·F·甘迺迪領導衛生與公眾服務部後，Moderna Inc（納斯達克股票代碼：MRNA）的股價下跌。這是您需要了解的內容。

What To Know: Kennedy has been a vocal critic of vaccines and mainstream medical practices, raising concerns about potential reforms at federal health agencies, including the FDA and NIH. Speculation about reduced funding, department eliminations and restructuring at the NIH has created unease among employees and investors. FDA staff are reportedly considering resignations due to concerns about Kennedy's potential policies.

須知：甘迺迪一直直言不諱地批評疫苗和主流醫療實踐，引起了人們對聯邦衛生機構（包括 FDA 和 NIH）潛在改革的擔憂。關於美國國立衛生研究院資金減少、部門撤銷和重組的猜測引起了員工和投資者的不安。據報道，由於擔心甘迺迪的潛在政策，FDA 工作人員正在考慮辭職。

Kennedy has proposed reducing the NIH's 27 divisions to 15 and replacing 600 employees, raising alarms about the future of federally funded research and its independence. Employees at the FDA and NIH are apprehensive about potential budget cuts and the politicization of research. For Moderna, this creates uncertainty about the future of vaccine development and approval processes.

甘迺迪提議將 NIH 的 27 個部門減少到 15 個，並更換 600 名員工，這對聯邦資助的研究的未來及其獨立性敲響了警鐘。 FDA 和 NIH 的員工對潛在的預算削減和研究政治化感到擔憂。對 Moderna 來說，這為疫苗開發和審批流程的未來帶來了不確定性。

Industry representatives, including the Pharmaceutical Research and Manufacturers of America, have expressed concerns about preserving innovation and maintaining the U.S.'s leadership in drug development. Despite the uncertainty, they indicated they may collaborate with the incoming administration to address healthcare challenges.

包括美國藥物研究和製造商協會在內的行業代表對保留創新和維持美國在藥物開發方面的領導地位表示擔憂。儘管存在不確定性，但他們表示可能會與即將上任的政府合作應對醫療保健挑戰。

Why It Matters: These developments have heightened investor fears about the pharmaceutical sector, particularly vaccine developers like Moderna, which rely on federal approval processes and public trust in immunization programs.

重要性：這些事態發展加劇了投資者對製藥業的擔憂，尤其是像 Moderna 這樣的疫苗開發商，這些公司依賴聯邦審批程序和公眾對免疫計畫的信任。

The uncertainty surrounding federal health policies and their impact on vaccine programs is driving the sell-off in Moderna and other vaccine stocks. Shares are under pressure as investors weigh the potential for reduced government support and a more challenging regulatory environment.

聯邦衛生政策的不確定性及其對疫苗計劃的影響正在推動 Moderna 和其他疫苗股票的拋售。由於投資者權衡政府支持減少的可能性和更具挑戰性的監管環境，股價面臨壓力。

MRNA Price Action: Moderna shares were down by 6.16% at $37.33 at the time of writing, according to Benzinga Pro.

MRNA 價格走勢：據 Benzinga Pro 稱，截至撰寫本文時，Moderna 股價下跌 6.16%，至 37.33 美元。

Read Next:

閱讀下一篇：